BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer

BACKGROUND: While the BRAF V600E mutation occurs in 5%–15% of metastatic colorectal cancer (mCRC), BRAF non-V600E mutations were recently reported to range from 1.6% to 5.1%. We have previously reported that BRAF non-V600E mutations could have a negative impact on efficacy outcomes as well as BRAF V...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Daisuke, Bando, Hideaki, Taniguchi, Hiroya, Masuishi, Toshiki, Komatsu, Yoshito, Yamaguchi, Kensei, Nakajima, Takako, Satoh, Taroh, Nishina, Tomohiro, Esaki, Taito, Nomura, Shogo, Takahashi, Koji, Iida, Shinobu, Matsuda, Seiko, Motonaga, Shinya, Fuse, Nozomu, Sato, Akihiro, Fujii, Satoshi, Ohtsu, Atsushi, Ebi, Hiromichi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046405/
https://www.ncbi.nlm.nih.gov/pubmed/33551068
http://dx.doi.org/10.1136/esmoopen-2019-000624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046405/
https://www.ncbi.nlm.nih.gov/pubmed/33551068
http://dx.doi.org/10.1136/esmoopen-2019-000624

Ejemplares similares